Home › Funds › Prosight Management, LP › IMRX

Prosight Management, LP position in IMRX

IMMUNEERING CORP · Health Care

Prosight Management, LP reported holding 150,000 shares of IMRX (IMMUNEERING CORP) in its Q3 2026 13F filing — a position valued at US$614K, representing 0.12% of its reported portfolio and ranking #31 among its reported holdings. Prosight Management, LP has disclosed IMRX holdings in 5 of the last 10 reported quarters, going back to Q2 2024.

Latest position (Q3 2026)150.00K sh
Reported value held$614.25K
Portfolio Weight0.12%
First reportedQ2 2024
Last changeAdd
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Prosight Management, LP's IMRX position evolved

Prosight Management, LP first disclosed a stake in IMRX in Q2 2024 at 550,000 shares (US$704K). Across 5 filings, Prosight Management, LP increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 150,000 shares valued at US$614K — an increase of 113,139 shares quarter over quarter.. Notable position changes include a 65% trim in Q3 2024 (shares fell 12% over the following quarter), a 70% trim in Q2 2026 (shares fell 18% over the following quarter), a 307% increase in Q3 2026 (shares fell 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 550.00K $704.00K New
Q3 2024 190.00K $473.10K Reduce
Q1 2026 123.41K $650.37K New
Q2 2026 36.86K $183.94K Reduce
Q3 2026 150.00K $614.25K Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About IMRX and 13F data

IMRX (IMMUNEERING CORP) is a Health Care company. 50 other funds we track also report a position in IMRX — the largest reported positions include Sanofi (US$11.1M), DCF Advisers, LLC (US$3.5M), ALETHEA CAPITAL MANAGEMENT, LLC (US$1.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding IMRX

All IMRX fund holders →

FAQ

How long has Prosight Management, LP held IMRX?

Prosight Management, LP has disclosed IMRX holdings in 5 of the last 10 reported quarters, going back to Q2 2024.

What is Prosight Management, LP's current position in IMRX?

As of Q3 2026, Prosight Management, LP holds 150.00K shares of IMRX (IMMUNEERING CORP), valued at $614.25K, representing 0.12% of its reported portfolio and ranking #31.

Has Prosight Management, LP been buying or selling IMRX?

In the latest 13F filing (Q3 2026), Prosight Management, LP increased its position in IMRX.

Which other funds hold IMRX?

Other major institutional holders of IMRX include Sanofi, DCF Advisers, LLC, ALETHEA CAPITAL MANAGEMENT, LLC, among 50 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.